"Evolocumab Lowers LDL-C in Diabetic Patients on Maximum Statins" - Marilynn Larkin
In patients with type 2 diabetes and hyperlipidemia or mixed dyslipidemia on a maximally tolerated statin, treatment with evolocumab lowers low-density-lipoprotein cholesterol (LDL-C) and improves levels of other lipids, according to researchers at the Icahn School of Medicine at Mount Sinai. "BANTING was a trial of type 2 diabetes patients who received standard-of-care therapy including moderate-to-high-intensity statins and anti-diabetic treatment," said author Robert Rosenson, MD, professor of medicine, cardiology, and director of Cardiometabolic disorders at the Icahn School of Medicine at Mount Sinai. "There was an improvement in fasting lipids and no change in glucose, insulin, or hemoglobin A1c. These results are consistent with previous studies."
— Robert Rosenson, MD, Professor, Medicine, Cardiology, Director, Cardiometabolic Disorders, Icahn School of Medicine at Mount Sinai